The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
 
Toni Choueiri
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; bicycle; Bicycle Therapeutics; Bristol-Myers Squibb; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Todd Bauer
Employment - Tennessee Oncology
Consulting or Advisory Role - Bayer; Lilly; Pfizer
Speakers' Bureau - Bayer; Lilly
Travel, Accommodations, Expenses - Pfizer
 
Jaime Merchan
Consulting or Advisory Role - Merck
Research Funding - Arcus Biosciences (Inst); BioNTech (Inst); Corvus Pharmaceuticals (Inst); DynamiCure Biotechnology (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); IMUGENE (Inst); Merck (Inst); Peloton Therapeutics (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Seattle Genetics/Astellas (Inst); Sillajen (Inst); Tizona Therapeutics, Inc. (Inst); Tocagen (Inst); Trishula Therapeutics (Inst); Vyriad (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
David McDermott
Consulting or Advisory Role - alkermes; Arcus Biosciences; Bristol-Myers Squibb; Cullinan Oncology; Eisai; EMD Serono; exelixis; Iovance Biotherapeutics; Lilly; Merck; Pfizer; Synthekine; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
 
Robert Figlin
Employment - 4D Medical
Leadership - 4D Medical; 4Dx
Stock and Other Ownership Interests - 4Dx
Consulting or Advisory Role - Johnson & Johnson
Research Funding - Merck (Inst)
 
Edward Arrowsmith
Employment - Tennessee Oncology
Stock and Other Ownership Interests - OneOncology
Consulting or Advisory Role - Flatiron Health
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calistoga Pharmaceuticals (Inst); Celgene (Inst); Cephalon (Inst); Chorus (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Dana-Farber Cancer Institute (Inst); Eisai (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); Exelixis (Inst); F. Hoffmann LaRoche (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen Research & Development (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Millennium (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncogenex (Inst); Onyx (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Sarah Cannon Research Institute (Inst); Takeda (Inst); Tolmar (Inst)
Travel, Accommodations, Expenses - Flatiron Health; OneOncology
Other Relationship - Sarah Cannon Research Institute (Inst)
 
M. Dror Michaelson
Employment - Cullinan Oncology (I)
Leadership - Cullinan Oncology (I)
Stock and Other Ownership Interests - Cullinan Oncology (I)
Consulting or Advisory Role - Eisai; Exelixis; Janssen; Merck
Research Funding - Eisai; Janssen; Merck
 
Elisabeth Heath
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Caris Life Sciences; Janssen; Johnson & Johnson/Janssen; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Gilead Sciences; Novartis; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Calithera Biosciences (Inst); Caris Life Sciences (Inst); Corcept Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo Inc. (Inst); Eisai (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen Research & Development (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); POINT Biopharma (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Sanofi
Other Relationship - Caris Centers of Excellence
 
Anishka D’Souza
No Relationships to Disclose
 
Song Zhao
Consulting or Advisory Role - AstraZeneca; Janssen Oncology
Research Funding - Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Laurent Kassalow
Employment - Merck
 
Rodolfo Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Donna Vickery
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
Travel, Accommodations, Expenses - Merck
 
Scott Tykodi
Honoraria - CancerNetwork; FirstWord; OncLive/MJH Life Sciences; Targeted Oncology; Topline Bio
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Exelixis
Research Funding - AVEO (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); HiberCell (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending (Inst)